292 related articles for article (PubMed ID: 22301676)
1. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.
Leonhardt F; Zirlik K; Buchner M; Prinz G; Hechinger AK; Gerlach UV; Fisch P; Schmitt-Gräff A; Reichardt W; Zeiser R
Leukemia; 2012 Jul; 26(7):1617-29. PubMed ID: 22301676
[TBL] [Abstract][Full Text] [Related]
2. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
[TBL] [Abstract][Full Text] [Related]
3. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
[TBL] [Abstract][Full Text] [Related]
5. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
6. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.
Flynn R; Allen JL; Luznik L; MacDonald KP; Paz K; Alexander KA; Vulic A; Du J; Panoskaltsis-Mortari A; Taylor PA; Poe JC; Serody JS; Murphy WJ; Hill GR; Maillard I; Koreth J; Cutler CS; Soiffer RJ; Antin JH; Ritz J; Chao NJ; Clynes RA; Sarantopoulos S; Blazar BR
Blood; 2015 Jun; 125(26):4085-94. PubMed ID: 25852057
[TBL] [Abstract][Full Text] [Related]
7. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
Wossning T; Herzog S; Köhler F; Meixlsperger S; Kulathu Y; Mittler G; Abe A; Fuchs U; Borkhardt A; Jumaa H
J Exp Med; 2006 Dec; 203(13):2829-40. PubMed ID: 17130299
[TBL] [Abstract][Full Text] [Related]
8. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Hilgendorf I; Eisele S; Remer I; Schmitz J; Zeschky K; Colberg C; Stachon P; Wolf D; Willecke F; Buchner M; Zirlik K; Ortiz-Rodriguez A; Lozhkin A; Hoppe N; von zur Muhlen C; zur Hausen A; Bode C; Zirlik A
Arterioscler Thromb Vasc Biol; 2011 Sep; 31(9):1991-9. PubMed ID: 21700926
[TBL] [Abstract][Full Text] [Related]
9. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.
McAdoo SP; Reynolds J; Bhangal G; Smith J; McDaid JP; Tanna A; Jackson WD; Masuda ES; Cook HT; Pusey CD; Tam FW
J Am Soc Nephrol; 2014 Oct; 25(10):2291-302. PubMed ID: 24700868
[TBL] [Abstract][Full Text] [Related]
10. HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease.
Li J; Heinrichs J; Haarberg K; Semple K; Veerapathran A; Liu C; Anasetti C; Yu XZ
J Immunol; 2015 Jul; 195(2):717-25. PubMed ID: 26048147
[TBL] [Abstract][Full Text] [Related]
11. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
12. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.
Leng C; Gries M; Ziegler J; Lokshin A; Mascagni P; Lentzsch S; Mapara MY
Exp Hematol; 2006 Jun; 34(6):776-87. PubMed ID: 16728283
[TBL] [Abstract][Full Text] [Related]
13. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
[TBL] [Abstract][Full Text] [Related]
14. Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.
Mochizuki K; Meng L; Mochizuki I; Tong Q; He S; Liu Y; Purushe J; Fung H; Zaidi MR; Zhang Y; Reshef R; Blazar BR; Yagita H; Mineishi S; Zhang Y
Blood; 2016 Jun; 127(25):3270-80. PubMed ID: 27143255
[TBL] [Abstract][Full Text] [Related]
15. The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells.
Platt AM; Benson RA; McQueenie R; Butcher JP; Braddock M; Brewer JM; McInnes IB; Garside P
Rheumatology (Oxford); 2015 Jan; 54(1):169-77. PubMed ID: 25065010
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice.
Schmidt F; Hilger N; Oelkrug C; Svanidze E; Ruschpler P; Eichler W; Boldt A; Emmrich F; Fricke S
Cytometry A; 2015 Apr; 87(4):334-45. PubMed ID: 25717029
[TBL] [Abstract][Full Text] [Related]
17. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
Radhakrishnan SV; Palaniyandi S; Mueller G; Miklos S; Hager M; Spacenko E; Karlsson FJ; Huber E; Kittan NA; Hildebrandt GC
Biol Blood Marrow Transplant; 2015 Jan; 21(1):30-8. PubMed ID: 25445642
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ
Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466
[TBL] [Abstract][Full Text] [Related]
19. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
